Opsona Abstracts

2018

A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2)
Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower
Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior
Hypomethylating Agent (HMA) Therapy
Garcia-Manero G, Jabbour E, Konopleva MY, Daver NG, Borthakur G, DiNardo GD, Bose P, Patel P, Komrokji RS, Shastri A, Roboz GJ, Miller RM, Arbe-Barnes S, Reilly M, McGuirk P, Kearney T, Keogh B, Kantarjian HM.
American Society for Hematology, 1st-4th December 2018, San Diego, USA.

TLR2 inhibition for cancer therapy, a novel approach with Tomaralimab a humanised IgG4 antibody
Keogh B, McGuirk P, Kearney T, Alvero A, Mor G, Gupta S, Garcia-Manero G, Wei Y, Jenkins B, Miller R, Reilly M.
EORTC, Molecular Targets & Cancer Therapeutics, November 13th-16th 2018, Dublin.

TLR2 inhibition reprograms the tumor microenvironment and delays progression of recurrent ovarian cancer in vivo
Alvero AB, Pitruzzello M, Keogh B, McGuirk P, Reilly M, Mor GG.
EORTC, Molecular Targets & Cancer Therapeutics, November 13th-16th 2018, Dublin.

Role of TLR2 in Oesophageal Adenocarcinoma (OAC) Progression
Flis E, Keogh B, McGuirk P, Murray J, Creagh E.
Irish Society of Immunology, 30th-31st Aug 2018, Dublin

2017

Phase II Study OPN-305, a (TLR-2) Antibody, in patients with lower risk myelodysplastic syndromes with prior hypomethylating agent (HMA) therapy
Garcia-Manero G, Montalban-Bravo G, Yang H, Wei Y, Alvarado Y, DiNardo C, Daver N, Konopleva M, Hearn K, Miller R, Arbe-Barnes S, McGuirk P, Kearney T, Keogh B, Kantarjian H, Reilly M.
European Hematology Association, June 22nd-25th 2017, Madrid.

Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzhemier’s Disease
Rubio-Araiz A, McDonald CL, Hennessy E, Keogh B, McGuirk P, Reilly M, Lynch MA.
13th International Conference on Alzheimer’s & Parkinson’s disease, Mar 29th – Apr 2nd 2017. Vienna.

2016

A Clinical Study of OPN-305, a Toll-like receptor 2 (TLR-2) antibody, in patients with Lower Risk Myelodysplastic Syndromes (MDS) that have received prior Hypomethylating Agent (HMA) Therapy
Garcia-Manero G, Montalban-Bravo G, Yang H, Wei Y, Alvarado Y, DiNardo C, Daver N, Konopleva M, Hearn K, Miller R, Arbe-Barnes S, McGuirk P, Kearney T, Keogh B, Kantarjian H, Reilly M.
American Society of Haematology (ASH), Dec 3rd-6th Dec 2016, San Diego

2012

Pre-Reperfusion Treatment with OPN-305, a Humanized Anti–Toll-Like Receptor-2 Antibody, Reduces Myocardial Ischemia/Reperfusion Injury in Pigs
Keogh B, Arslan F, Houtgraaf JH, Kazemi K, de Jong R, McCormack WJ, O’Neill LA, McGuirk P, Timmers L, Smeets MB, Akeroyd L, Reilly M, Pasterkamp G, de Kleijn DP.
European Congress of Immunology, Glasgow, Sep 5th-8th 2012.

2011

Monoclonal antibody inhibition of TLR2 promotes graft function in a murine model of renal transplantation
Farrar CA, Keogh B, McCormack W, O'Shaughnessy A, Parker A, Reilly M, Sacks SH European Society of Transplantation, Glasgow, September 2011

TLR2 inhibition by a specific monoclonal antibody promotes graft function in a murine model of renal transplantation
Farrar CA, Keogh B, McCormack W, O'Shaughnessy A, Parker A, Reilly M, Sacks SH TLR2011, Riva Del Garda, Italy, May 2011

2010

Inhibition of TLR2 promotes graft function in a murine model of renal transplantation
Farrar CA, Keogh B, McCormack W, O’Shaughnessy A, Parker A, Reilly M, Sacks SH.
BSI, Liverpool, December 2010

2009

Myocardial ischemia/reperfusion injury is mediated by leukocytic TLR2 and reduced by systemic administration of a novel anti-TLR2 antibody
Arslan F, Smeets MB, O'Neill LA, Keogh B, McGuirk P, Timmers L, Tersteeg C, Hoefer IE, Doevendans PA, Pasterkamp G, de Kleijn DP
Irish Society for Immunology, September 2009, Dublin, Ireland

Development of a specific TLR4 inhibitory peptide from the vaccinia virus protein A46
Lysakova T, Stack J, Harrington B, Keogh B, Bowie AG.
Pattern Recognition Molecules and Immune Sensors of Pathogens
Banff, Alberta, March 29 – April 3, 2009